Although many mature T cell lymphomas may not typically express the CD7 surface antigen, the exceptional safety and powerful efficacy demonstrated by our CD7-RTX CAR T therapy support its potential use and further investigation in tumors screened and found to have high homogenous CD7 expression, thereby advancing a personalized treatment approach. This evidence concerns the gene CD7 and T-cell non-Hodgkin lymphoma.